Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2012 1
2013 1
2014 1
2019 1
2021 3
2022 4
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

12 results

Results by year

Filters applied: . Clear all
Page 1
Re-examination of MAGE-A3 as a T-cell Therapeutic Target.
Martin AD, Wang X, Sandberg ML, Negri KR, Wu ML, Toledo Warshaviak D, Gabrelow GB, McElvain ME, Lee B, Daris ME, Xu H, Kamb A. Martin AD, et al. Among authors: toledo warshaviak d. J Immunother. 2021 Apr 1;44(3):95-105. doi: 10.1097/CJI.0000000000000348. J Immunother. 2021. PMID: 33284140 Free PMC article.
Potent, Selective CARs as Potential T-Cell Therapeutics for HPV-positive Cancers.
Wang X, Sandberg ML, Martin AD, Negri KR, Gabrelow GB, Nampe DP, Wu ML, McElvain ME, Toledo Warshaviak D, Lee WH, Oh J, Daris ME, Chai F, Yao C, Furney J, Pigott C, Kamb A, Xu H. Wang X, et al. Among authors: toledo warshaviak d. J Immunother. 2021 Oct 1;44(8):292-306. doi: 10.1097/CJI.0000000000000386. J Immunother. 2021. PMID: 34432728 Free PMC article.
HLA-A∗02-gated safety switch for cancer therapy has exquisite specificity for its allelic target antigen.
Mock JY, Winters A, Riley TP, Bruno R, Naradikian MS, Sharma S, Jette CA, Elshimali R, Gahrs C, Toledo-Warshaviak D, West AP Jr, Kamb A, Hamburger AE. Mock JY, et al. Among authors: toledo warshaviak d. Mol Ther Oncolytics. 2022 Oct 4;27:157-166. doi: 10.1016/j.omto.2022.09.010. eCollection 2022 Dec 15. Mol Ther Oncolytics. 2022. PMID: 36381658 Free PMC article.
A rational approach to assess off-target reactivity of a dual-signal integrator for T cell therapy.
Wang X, Wong LM, McElvain ME, Martire S, Lee WH, Li CZ, Fisher FA, Maheshwari RL, Wu ML, Imun MC, Murad R, Toledo Warshaviak D, Yin J, Kamb A, Xu H. Wang X, et al. Among authors: toledo warshaviak d. Toxicol Appl Pharmacol. 2022 Feb 15;437:115894. doi: 10.1016/j.taap.2022.115894. Epub 2022 Jan 25. Toxicol Appl Pharmacol. 2022. PMID: 35085592 Free article.
Mesothelin-specific CAR-T cell therapy that incorporates an HLA-gated safety mechanism selectively kills tumor cells.
Tokatlian T, Asuelime GE, Mock JY, DiAndreth B, Sharma S, Toledo Warshaviak D, Daris ME, Bolanos K, Luna BL, Naradikian MS, Deshmukh K, Hamburger AE, Kamb A. Tokatlian T, et al. Among authors: toledo warshaviak d. J Immunother Cancer. 2022 Jan;10(1):e003826. doi: 10.1136/jitc-2021-003826. J Immunother Cancer. 2022. PMID: 35091455 Free PMC article.
Chimeric Antigen Receptors Directed at Mutant KRAS Exhibit an Inverse Relationship Between Functional Potency and Neoantigen Selectivity.
Tokatlian T, Asuelime GE, Naradikian MS, Mock JY, Daris ME, Martin AD, Toledo Warshaviak D, Kamb A, Hamburger AE. Tokatlian T, et al. Among authors: toledo warshaviak d. Cancer Res Commun. 2022 Jan 28;2(1):58-65. doi: 10.1158/2767-9764.CRC-21-0165. eCollection 2022 Jan. Cancer Res Commun. 2022. PMID: 36860694 Free PMC article.
12 results